TD Cowen, a well-known financial institution, initiated coverage on Cullinan Oncology's stock with an Outperform rating. This positive rating indicates that the company is expected to perform better than its peers in the market, leading to an increase in its stock price. As a result, investors are likely to view this news positively, driving the stock price higher in the short term.